Comparison of prognostic factors and outcome of patients with advanced cervical cancer between Han and Uygur in Xinjiang district
10.3760/cma.j.issn.1004-4221.2012.06.017
- VernacularTitle:新疆地区维吾尔族和汉族中晚期宫颈癌疗效比较及预后因素分析
- Author:
Lei ZHANG
;
Yongxing BAO
- Publication Type:Journal Article
- Keywords:
Uygur patients;
Han patient;
Cervical neoplasms/radiotherapy;
Cervical neoplasms/radiochemotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2012;(6):540-542
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the treatment outcome and prognostic factors in patients with advanced cervical cervical cancer between Han and Uygur in Xinjiang district.Methods 204 patients with advanced cervical cancer were retrospectively analyzed.Eighty patients were Han 80 and 124 were Uyghur.100 patients received radiotherapy alone and 49 with concurrent radiochemotherapy,and 55 had brachytherapy followed by surgery.The survival rate was calculated by Kaplan-Meier method and the difference was compared by Logrank test.Multivariate analysis was performed using Cox regression model.Results The follow-up rate was 97.5％.The number of patients with at least 5 years of follow up was 102.The 1-,3-and 5-year overall survival rates in Han and Uygur patients were 81.2％,66.3％,51.4％ and 83.4％,62.8％,49.2％,respectively (x2 =3.21,P =0.273).Univariate analysis showed that parity,geographical distribution,pathological type,clinical stage,lymph node involvement and treatment were prognostic factors for overall survival (x2 =2.35,11.34,7.12,6.73,4.79,13.60,P=0.049,0.029,0.031,0.037,0.041,0.021).Multivariate analysis showed that parity,geographical distribution,pathological type,clinical stage,lymph node involvement and treatment were independent prognostic factors for overall survival (x2 =8.36,24.94,10.69,5.63,9.50,P =0.002,0.001,0.021,0.018,0.031).Conclusions There is no significant difference in overall survival rate of patients with advanced cervical cancer between Han and Uighur.Patients with parity more than or equal to 3 times,advanced clinical stage or adenocarcinoma have poor prognoses.
